CDK4/6 Inhibitors: What Is the Best Cocktail?

被引：17
|
作者：
Malumbres, Marcos [1 ,2 ]
机构：
[1] Spanish Natl Canc Res Ctr CNIO, Cell Div, Madrid, Spain
[2] Spanish Natl Canc Res Ctr CNIO, Canc Grp, Madrid, Spain
来源：
CLINICAL CANCER RESEARCH | 2019年 / 25卷 / 01期
关键词：
D O I：
10.1158/1078-0432.CCR-18-2177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CDK4/6 inhibitors have shown great potential in the new armamentarium against cancer. However, their effect as single agents is limited, and the hopes are on new combinatory strategies. Recent data suggest that inhibiting mTOR may significantly cooperate with cell- cycle arrest in a variety of cancers.
引用
收藏
页码：6 / 8
页数：3
相关论文
共 50 条
  • [31] Senescence as a therapeutically relevant response to CDK4/6 inhibitors
    Verena Wagner
    Jesús Gil
    Oncogene, 2020, 39 : 5165 - 5176
  • [32] CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
    Yilan Yang
    Jurui Luo
    Xingxing Chen
    Zhaozhi Yang
    Xin Mei
    Jinli Ma
    Zhen Zhang
    Xiaomao Guo
    Xiaoli Yu
    Journal of Experimental & Clinical Cancer Research, 39
  • [33] CDK4/6 Inhibitors in the Treatment of Metastatic Breast Cancer
    Ettl, Johannes
    Huober, Jens
    Lueftner, Diana
    Marme, Frederik
    Wuerstlein, Rachel
    BREAST CARE, 2017, 12 (02) : 118 - 120
  • [34] Effect of CDK4/6 Inhibitors on Tumor Immune Microenvironment
    Liu, Jie
    Cheng, Min
    Xu, Jiamei
    Liang, Yue
    Yin, Beibei
    Liang, Jing
    IMMUNOLOGICAL INVESTIGATIONS, 2024, 53 (03) : 437 - 449
  • [35] CDK4/6 Inhibitors Represent Potential Psoriasis Therapeutics
    Brownell, I.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (11) : 2098 - 2098
  • [36] CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
    Arsenijevic, Tatjana
    Coulonval, Katia
    Raspe, Eric
    Demols, Anne
    Roger, Pierre P.
    Van Laethem, Jean-Luc
    CANCERS, 2023, 15 (03)
  • [37] CDK4/6 inhibitors in breast cancer: spotting the difference
    Jose Manuel Perez-Garcia
    Javier Cortes
    Antonio Llombart-Cussac
    Nature Medicine, 2021, 27 : 1868 - 1869
  • [38] The role of CDK4/6 inhibitors in early breast cancer
    Gil-Gil, Miguel
    Alba, Emilio
    Gavila, Joaquin
    de la Haba-Rodriguez, Juan
    Ciruelos, Eva
    Tolosa, Pablo
    Candini, Daniele
    Llombart-Cussac, Antonio
    BREAST, 2021, 58 : 160 - 169
  • [39] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Kharenko, Olesya A.
    Patel, Reena G.
    Calosing, Cyrus
    van der Horst, Edward H.
    CANCER GENE THERAPY, 2022, 29 (06) : 859 - 869
  • [40] Combination of ZEN-3694 with CDK4/6 inhibitors reverses acquired resistance to CDK4/6 inhibitors in ER-positive breast cancer
    Olesya A. Kharenko
    Reena G. Patel
    Cyrus Calosing
    Edward H. van der Horst
    Cancer Gene Therapy, 2022, 29 : 859 - 869
12345